Developing Novel Antibody Biologics to Address Unmet Medical Needs
Prestige Biopharma invests its expertise and resources in the development of first-in-class antibody therapeutics to fight life-threatening diseases. To bring innovation for life, we are developing novel monoclonal and bispecific antibody drugs that ensure stability and strong growth potential.

IDC005 🔍

: Highly aggressive tumors such as pancreatic cancer often feature extensive development of connective tissue, known as desmoplasia, and rapid growth of blood and lymphatic vessels, referred to as angiogenesis and lymph-angiogenesis. These processes are co-dependent. IDC005 is a bispecific antibody that targets desmoplasia and (lymph-)angiogenesis.

IDC007 🔍

: Systemic inflammatory response syndrome (SIRS) is a severe, often fatal cascade of exaggerated immune responses. It can be caused by infectious and autoimmune diseases such as COVID-19 and lupus, and immunotherapies like T-cell based therapies and immune checkpoint inhibitors. IDC007 is a bispecific antibody that suppresses two key molecules in the development of CRS.

IDC008 🔍

: More than 80% of cancer patients do not respond to treatment by immune checkpoint inhibitors, which is a challenge seen in tumors with severely immune-suppressed tumor microenvironment (TME). Another challenge is that some patients are susceptible to the drugs’ off-target adverse effects. IDC008 is a bispecific antibody that targets PAUF and an immune checkpoint molecule expressed in tumors. Targeting PAUF increases the selectivity of the immune checkpoint inhibition and alleviates TME immune suppression, at the same time.


First-in-Class Antibody Pipeline

Category

Pipeline

Indication

Development Stage

Monoclonal
Antibody

PBP1510
(Ulenistamab)

Pancreatic cancer,
Ovarian cancer

Phase 1/2a Clinical Trial in Europe and U.S.

Monoclonal
Antibody

PBP1710
(Anti-CTHRC1)

Solid Tumors

Preparing for preclinical trial

Bispecific
Antibody

IDC001

Pancreatic cancer,
Ovarian cancer

Cloning

Bispecific
Antibody

IDC002

Pancreatic cancer,
Ovarian cancer

Discovery

Bispecific
Antibody

IDC003

Solid Tumors

Discovery

Bispecific
Antibody

IDC004

Pancreatic cancer,
Ovarian cancer

Discovery

Bispecific
Antibody

IDC005

Solid Tumors

Developing candidate

Bispecific
Antibody

IDC006

Breast cancer,
Metastatic gastric cancer

Discovery

Bispecific
Antibody

IDC007

Viral infectious disease

Developing candidate

Bispecific
Antibody

IDC008

Pancreatic cancer,
Ovarian cancer

Developing candidate

Bispecific
Antibody

IDC009

Pancreatic cancer,
Ovarian cancer

Discovery

Bispecific
Antibody

IDC010

Solid Tumors

Developing candidate